Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Intrinsic Value
Beijing SL Pharmaceutical Co., Ltd. engages in the development of new drugs. [ Read More ]
The intrinsic value of one Beijing SL Pharmaceutical Co Ltd stock under the Base Case scenario is 4.92 CNY. Compared to the current market price of 8.62 CNY, Beijing SL Pharmaceutical Co Ltd is Overvalued by 43%.
Valuation Backtest
Beijing SL Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Beijing SL Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Beijing SL Pharmaceutical Co Ltd
| Current Assets | 2B |
| Cash & Short-Term Investments | 1.4B |
| Receivables | 225.5m |
| Other Current Assets | 418m |
| Non-Current Assets | 4B |
| Long-Term Investments | 2B |
| PP&E | 544.3m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 476.1m |
| Current Liabilities | 276.7m |
| Accounts Payable | 176.3m |
| Accrued Liabilities | 30.4m |
| Other Current Liabilities | 70m |
| Non-Current Liabilities | 127.6m |
| Other Non-Current Liabilities | 127.6m |
Earnings Waterfall
Beijing SL Pharmaceutical Co Ltd
|
Revenue
|
999.8m
CNY
|
|
Cost of Revenue
|
-187.7m
CNY
|
|
Gross Profit
|
812.1m
CNY
|
|
Operating Expenses
|
-639.5m
CNY
|
|
Operating Income
|
172.7m
CNY
|
|
Other Expenses
|
141.4m
CNY
|
|
Net Income
|
314m
CNY
|
Free Cash Flow Analysis
Beijing SL Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Beijing SL Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Beijing SL Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing SL Pharmaceutical Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Beijing SL Pharmaceutical Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing SL Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Beijing SL Pharmaceutical Co Ltd is 42.72 CNY .
Shareholder Return
Price
Beijing SL Pharmaceutical Co Ltd
| Average Annual Return | -12.3% |
| Standard Deviation of Annual Returns | 14.93% |
| Max Drawdown | -54% |
| Market Capitalization | 8.9B CNY |
| Shares Outstanding | 1 028 093 800 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beijing SL Pharmaceutical Co., Ltd. engages in the development of new drugs. The company is headquartered in Beijing, Beijing and currently employs 761 full-time employees. The company went IPO on 2004-09-09. The firm's main products include complex coenzyme, arsenic trioxide, recombinant human granulocyte stimulating factor, recombinant human interleukin-2, recombinant human basic fibroblast growth factor, thymopentin, enoxaparin and Xingling dropping pills, among others. The firm distributes its products in domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Beijing SL Pharmaceutical Co Ltd stock under the Base Case scenario is 4.92 CNY.
Compared to the current market price of 8.62 CNY, Beijing SL Pharmaceutical Co Ltd is Overvalued by 43%.
You don't have any saved screeners yet
